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Robert A. Falconer *
The polysialyltransferases (polySTs) catalyse the polymerisation of polysialic acid, which plays an impor-
tant role in tumour metastasis. While assays are available to assess polyST enzyme activity, there is no
methodology available specifically optimised for identification and quantitative evaluation of potential
polyST inhibitors. The development of an HPLC-fluorescence-based enzyme assay described within
includes a comprehensive investigation of assay conditions, including evaluation of metal ion compo-
sition, enzyme, substrate and acceptor concentrations, temperature, pH, and tolerance to DMSO, fol-
lowed by validation using known polyST inhibitors. Thorough analysis of each of the assay components
provided a set of optimised conditions. Under these optimised conditions, the experimentally observed Ki
value for CMP, a competitive polyST inhibitor, was strongly correlated with the predicted Ki value, based
on the classical Cheng–Prusoff equation [average fold error (AFE) = 1.043]. These results indicate that this
assay can provide medium-throughput analysis for enzyme inhibitors with high accuracy, through deter-
mining the corresponding IC50 values with substrate concentration at the KM, without the need to
perform extensive kinetic studies for each compound. In conclusion, an in vitro cell-free assay for accu-
rate assessment of polyST inhibition is described. The utility of the assay for routine identification of
potential polyST inhibitors is demonstrated, allowing quantitative measurement of inhibition to be
achieved, and exemplified through assessment of full competitive inhibition. Given the considerable and
growing interest in the polySTs as important anti-metastatic targets in cancer drug discovery, this is a vital
tool to enable preclinical identification and evaluation of novel polyST inhibitors.
1. Introduction
Polysialyltransferases (polySTs), specifically enzymes ST8SiaII
and ST8SiaIV, catalyse the biosynthesis of polysialic acid
(polySia), which is a unique carbohydrate homopolymer of
N-acetylneuraminic acid (sialic acid, Neu5Ac), linked specifi-
cally by α-2,8 glycosidic bonds. PolySia is found on several pro-
teins in humans, but is predominantly observed as a post-
translational modification of the neural cell adhesion mole-
cule (NCAM). Whilst polySTs are active embryologically, with
roles including driving the polySia-dependent migration of
cells of neural crest origin in the foetus, polySia expression is
generally dramatically reduced post-partum,1,2 with relatively
low level polySia expression only detectable in discrete areas of
the brain, and in blood, milk, semen, and on immune cells.2–7
Crucially, significant polySia expression is observed in many
cancers, principally those of neuroendocrine origin, where the
expression of polySTs is re-capitulated and is associated with
tumour cell migration, invasion, and the events associated
with metastasis. This is closely correlated with poor prognosis
in the clinic.8–14 The polySTs, and ST8SiaII in particular (gen-
erally thought to be the dominant enzyme in tumours where
polySia is expressed8,15), have significant potential as drug
targets in a number of difficult-to-treat cancers, notably neuro-
blastoma and small cell lung cancer.8,16
A number of in vitro assays have been developed and
reported for the evaluation of polyST enzyme activity, utilising
the enzyme, the substrate CMP-sialic acid, and the acceptor
NCAM.17–19 The Gerardy-Schahn group recently reported the
utility of a non-ganglioside fluorescent acceptor, DMB-DP3, as
a convenient substitute for NCAM, enabling analysis of poly-
merisation. DMB-DP3 is a trimer (degree of polymerisation,
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DP = 3) of α-2,8-linked sialic acid (‘DP3’) derivatised with a
fluorescent 1,2-diamino-4,5-methylenedioxybenzene (DMB)
label thereby forming ‘DMB-DP3’. This was successfully
employed to assess bacterial and murine ST8SiaII enzyme
activity.18 Building on this work, we previously utilised
DMB-DP3 to determine the activity of human polySTs, moni-
toring polymerisation of DMB-DP3 to predominantly
DMB-DP4 (Fig. 1).20 The fluorescent acceptor and product in
the enzyme reaction are separated by reversed-phase chromato-
graphy over a short timeframe (10 min), while being simul-
taneously visualised by fluorescence detection (Fig. 1, inset),
allowing rapid analysis. Whilst adequate for measurement of
enzyme activity, this assay lacks the characteristics to deduce
accurate kinetics required for detailed analysis of potential
enzyme inhibitors.
In our research focused on the identification of novel
polyST inhibitors, we require a reproducible medium-through-
put quantitative assay for determination of enzyme inhibition,
with the key additional requirement for robust detailed
enzyme kinetics information, and compound mode of inhi-
bition (i.e. competitive or non-competitive).20,21 Herein we
report a cell-free polyST assay that meets these demands. We
have systematically investigated the assay parameters that are
predicated to influence the underlying enzyme catalysis with a
view to providing a sound basis on which to reliably determine
mode of inhibition, IC50 and Ki values for putative inhibitors,
the latter through both prediction and experiment. The opti-
mised assay conditions were validated by evaluating known
polyST small molecule inhibitors.
2. Materials and methods
2.1 Reagents
The following materials were obtained from Sigma-Aldrich,
UK: cytidine-5′-monophospho-N-acetylneuraminic acid sodium
salt (CMP-Sia, C8271), 4,5-methylenedioxy-1,2-phenylene-
diamine dihydrochloride (DMB, D4784), anhydrous mag-
nesium chloride (MgCl2, M8266), manganese chloride (MnCl2,
8054), potassium chloride (KCl, P9333), sodium cacodylate tri-
hydrate (C4945), glycerol solution (G5516), ammonium
formate (AmF, F-2004), β-mercaptoethanol (M-7522), dimethyl
sulfoxide (DMSO, D8418), trifluoroacetic acid: (98% Reagent
Grade, T6508) and sodium hydrosulfite (157951).
N-Acetylneuraminic acid trimer DP3 (α,2–8) was purchased
from Nacalai Tesque, Japan (00641-52). Human ST8SiaII
recombinant protein was purchased from R&D systems
(6590-GT, USA). Tris-base was purchased from Fisher
Bioreagents UK (BP152-1). Sodium hydroxide was obtained
from Alfa Aesar (A16037). The reversed-phase chromatography
column (RPB, 2.1 × 250 mm, 5 µm particle size) was purchased
from Hichrom Ltd, UK.
2.2 DMB-DP3 synthesis and purification
DMB-DP3 synthesis was conducted as described previously.20
Briefly, DP3 (10 mg ml−1) was dissolved in a labelling solution
containing DMB (20 mM), sodium hydrosulfite (40 mM) and
β-mercaptoethanol (1 M). The mixture was then added to an
equal volume of ice-cold trifluoroacetic acid (40 mM), followed
by incubation at 4 °C overnight. The reaction was subsequently
Fig. 1 The polysialyltransferase (polyST) enzyme reaction and analysis by HPLC; the enzyme reaction, polymerisation of DMB-DP3 (acceptor, as a
substitute for NCAM) to DMB-DP4/DMB-DP5 catalysed by polyST, utilising CMP-Sia as substrate; [inset] an extract from a reversed-phase HPLC flu-
orescence chromatogram showing the DMB-DP3 acceptor, and DMB-DP4 and DMB-DP5 products from the enzyme reaction.
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quenched by addition of one fifth of the reaction volume of
sodium hydroxide (0.2 M). The synthesised DMB-DP3 was sub-
sequently purified on a reversed-phase liquid chromatography-
fluorescence detection system, as previously described.20
2.3 Enzyme assay characterisation
The initial polyST enzyme assay conditions were as described
previously for the assessment of enzyme activity,20 with minor
modifications. Specifically, recombinant polyST (ST8SiaII)
protein (250 ng) and DMB-DP3 (50 µM) were added to a solu-
tion containing MgCl2 (20 mM), MnCl2 (10 mM), 5% glycerol,
and sodium cacodylate (10 mM, pH 6.7, adjusted by addition
of HCl). The reaction was initiated by addition of the substrate,
CMP-Sia (500 µM), and maintained at 25 °C for 2 h. The final
reaction volume was 10 µl. The enzyme reaction was quenched
by addition of 9 volumes of a stopping buffer containing Tris-
HCl (100 mM, pH 8.0) and EDTA (20 mM), followed by incu-
bation at 50 °C for 10 min. A 90% methanol precipitation step
was then performed to remove the recombinant proteins prior
to HPLC-fluorescence analysis, using centrifugation at 14 000
rpm (20 000g).
2.3.1 Effect of metal ions. Enzyme reactions containing
sodium cacodylate buffer (10 mM, pH 6.7), DMB-DP3 (50 µM)
and polyST protein (250 ng) were incubated with either Mg2+,
Mn2+ or K+ ions, in concentrations ranging from 1–100 mM, as
indicated in Fig. 2. Reactions were initiated by adding CMP-Sia
(100 µM), and were carried out at 25 °C for 2 h as described
above. The residual enzymatic activities were measured to
evaluate the effects of metal ions on enzymatic activity.
2.3.2 Effect of incubation temperature. Analysis of enzyme
kinetic parameters was carried out at a range of temperatures
(10 °C, 15 °C, 20 °C, 25 °C, 30 °C, and 37 °C). In brief, enzyme
reactions were incubated in the presence of the metal ion com-
position identified as optimal, while the remaining assay com-
ponents were as described above, at each temperature of inter-
est at pre-determined time points (0.5 h, 1 h, 2 h, 3 h, and
5 h). The initial velocities were evaluated to determine the cata-
lytically optimum temperature.
2.3.3 Effect of incubation pH. Enzyme kinetics were
characterised in a pre-designated pH environment containing
various substrate concentrations. In brief, enzyme reactions
were performed in buffer containing the previously deter-
mined optimal metal ion composition, cacodylate (10 mM) at
a pH ranging from 4.90 to 7.20, and CMP-Sia (10–1000 µM), at
25 °C for pre-determined time points (0.5 h, 1 h, 2 h, 3 h, and
5 h). The initial velocities were evaluated to determine the
optimum pH and the corresponding KM values of substrate
(CMP-Sia).
2.3.4 Effect of enzyme concentration. Kinetic parameters
for polyST (5–100 ng µL−1) were analysed by performing the
enzyme assay in buffer containing the optimal metal ion com-
position, and temperature identified from the above, in the
presence of CMP-Sia (500 µM) and DMB-DP3 (200 µM).
Reactions were carried out for each enzyme concentration of
interest at pre-determined time points (0.5 h, 1 h, 2 h, 3 h, and
4.5 h), in both the optimal and original pH environments. To
avoid saturation of fluorescence detection, samples were
diluted at least 10-fold.
2.3.5 Analysis of the KM of acceptor (DMB-DP3).
Subsequently, the apparent affinity constant (KM) of DMB-DP3
for polyST was determined by carrying out the enzymatic reac-
tions under the optimal conditions, in the presence of
DMB-DP3 at various concentrations (10–300 µM). The corres-
ponding initial velocities were determined.
2.3.6 Effect of DMSO. This was carried out by incubating
enzymatic reactions in the optimised buffer containing
CMP-Sia (24 µM) and polyST (250 ng) at pH 5.8 (the optimised
pH determined above), in the presence of DMSO at various
concentrations (0%, 1%, 2%, 5%) at 25 °C, at pre-determined
time points (0.5 h, 1 h, 2 h, 3 h, and 5 h). The initial velocities
were determined to evaluate DMSO tolerance.
2.4 HPLC-fluorescence analysis of polyST catalytic activity
PolyST enzymatic activity was determined by analysis of the
conversion of DMB-DP3 to DMB-DP4 (and DMB-DP5, which is
often additionally detected), using a reversed-phase HPLC
system in conjunction with fluorescence detection. Samples
for analysis were subjected to separation with a reversed-phase
chromatographic column (2.1 × 250 mm, 5 µm, RPB-Hichrom,
UK) eluting with methanol (16% in HPLC grade water) and
ammonium formate (5 mM) using an isocratic mobile phase
(350 µl min−1) at 20 °C. Each chromatographic separation was
conducted over 10 min. The DMB-labelled acceptor
(DMB-DP3) and products (DMB-DP4 & DMB-DP5) were visual-
ised using a fluorescence detector (Ex 373 nm/Em 448 nm (ref.
20)). The acquired chromatograms were analysed by Masslynx
and Quanlynx software (Waters, UK).
2.5 Assessment relative potencies (IC50 values) for polyST
inhibitors
For determination of IC50 values for known polyST inhibitors
(CMP, and 5-methyl-CMP), enzymatic reactions were carried
Fig. 2 Effects of individual metal ions on polyST enzymatic activity.
Data plotted are mean values ± SD from 3 independent experiments.
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out in the presence of each compound at pre-determined con-
centrations for 2 h. Enzyme reactions were carried out in the
presence of 24 µM substrate (CMP-Sia), which is the KM at the
optimised conditions (see below). Experiments were per-
formed in triplicate.
2.6 Assessment of inhibitory constant (Ki) for CMP
In order to determine inhibitory constant (Ki) for the known
polyST inhibitor CMP, enzymatic reactions were performed in
the presence of the inhibitor at each single concentration, with
increasing concentrations of CMP-Sia substrate (0.5–5 KM) at
25 °C at selected time points (specifically, 0.5, 1, 2, 3, and 5 h).
Experiments were performed in triplicate.
2.7 Kinetics data analysis
PolyST enzymatic conversion of fluorescent acceptor
(DMB-DP3) to fluorescent products (DMB-DP4 and DMB-DP5)
was calculated from fluorescence signal peak areas (measured
as Relative Fluorescence Units, RFU) of products and acceptor
molecules, according to eqn (1):
%PolyST enzymatic conversion ¼ RFUðProductsÞ=
½RFUðProductsÞ þ RFUðAcceptorÞ ð1Þ
Enzymatic transfer of Sia from substrate (CMP-Sia) to fluo-
rescent acceptor was calculated from the percentage concen-
tration of transferred Sia against total substrate concentration,
according to eqn (2):
%Conversion½CMP‐Sia ¼
%Enzymatic conversion ½Acceptor=½Substrate ð2Þ
Percent enzyme inhibition was calculated using the % con-
version values, based on eqn (1), obtained in the presence and
absence of inhibitor according to the eqn (3):
% Inhibition ¼ ½1 Conversion ðiÞ=Conversion ðCÞ  100%
ð3Þ
Inhibitor compound potency (IC50 value) was determined
by plotting percentage inhibition as a function of inhibitor
concentration and fitting in a normalised dose–response non-
linear regression curve, using Graphpad Prism 6 software.
Initial velocities (v0) for enzymatic reactions were calculated
using differential equations derived from the respective
enzyme reaction progress curves, using a time point of 0.01 h.
The enzyme kinetics parameters were calculated by plotting
initial reaction velocities [v0] versus substrate concentration [S]
and fitting the data points by non-linear regression to the clas-
sical Michaelis–Menten steady-state model:
V0 ¼ V ðappÞmax  ½S=ð½S þ K ðappÞM Þ ð4Þ
where v0 is the initial reaction velocity (pmol min
−1), [S] rep-
resents the substrate concentration (µM), VðappÞmax is the apparent
maximum reaction velocity (pmol min−1) and KðappÞM is the
apparent Michaelis constant (µM).
The catalytic constant for the enzyme was estimated by the
eqn (5), assuming a molecular mass of 41 kDa per subunit of
ST8SiaII:
kcat ¼ Vmax=½ETotal ð5Þ
where kcat is the catalytic constant (min
−1), Vmax is the
maximum reaction velocities (µM min−1) and [ETotal] is the
total enzyme concentration (µM).
The accuracy of the prediction for experimentally-measured
intrinsic potency (Ki) values from half apparent potencies
(IC50/2) was determined by calculating the average fold error
(AFE) according to eqn (6).22
AFE ¼ 10 exp ½1=n
X
logðPredicted K i=measured K iÞ ð6Þ
This methodology is based on absolute values of the logar-
ithm of the ratio of predicted to measured values, so that nega-
tive values are also converted to positive values. An AFE value
of 1 represents an ideal prediction.22
All data points presented are representative of 3 indepen-
dent experiments, each with a minimum of 2 technical
replicates.
3. Results and discussion
3.1 Assay development
Measuring the effect of small molecules on the cell-free cata-
lytic activity of polyST is an effective way to identify novel
inhibitors of this enzyme. Existing assays reported in the litera-
ture have focused on maximising enzyme activity, rather than
providing the optimum conditions to measure enzyme inhi-
bition, or to derive important information about mode of inhi-
bition and kinetics data. We have thus undertaken an explora-
tion of the reaction conditions, and have arrived at an assay
with highly effective capability for inhibitor detection, includ-
ing determination of Ki values and mode of inhibition. Given
that ST8SiaII is the predominant of the two polySTs in cancer,
this enzyme was the focus for these studies.
3.1.1 Metal ion composition. Previously published assays
for polyST activity have reported methodologies that include
varying combinations and concentrations of magnesium
(Mg2+), manganese (Mn2+), potassium (K+), and indeed
calcium (Ca2+) ions.20,21,23–28 While Kitazume-Kawaguchi most
recently suggested that metal ions are not required for human
polyST enzyme activity,23 Kojima had earlier provided evidence
that activity was enhanced by both Mg2+ and Mn2+ ions at
10 mM, in the case of recombinant polyST enzymes,24,25 albeit
utilising NCAM as acceptor in each case.
We observed that polyST was significantly more active in
the presence of Mn2+ than Mg2+ up to a concentration of
20 mM (Fig. 2). Higher concentrations of either ion led to a
reduction in enzyme activity, as measured by conversion of
acceptor DMB-DP3 to products DMB-DP4/DMB-DP5. This is in
agreement with previous studies suggesting that Mn2+ was
more important for human polyST activities than Mg2+.24,26,29
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K+ ions exhibited very little effect on enzyme activity, while
Mn2+ and Mg2+ ions significantly improved enzymatic activity
(as compared to the control) up to a concentration of 40 mM,
above which activity was reduced. Both divalent cations signifi-
cantly improved enzyme activity at 20 mM. Furthermore, we
demonstrated that the effects were not additive (Fig. S1†). The
optimum metal ion composition in the enzyme assay buffer
was thus selected as 20 mM MnCl2, in the absence of MgCl2
and KCl.
3.1.2 Effect of incubation temperature on enzyme activity.
The effect of temperature on human polyST was investigated,
by analysing enzyme reaction velocities at selected tempera-
tures between 10 °C and 37 °C (Fig. 3). Results demonstrated a
peak activity between 20–25 °C. Similarly to observations
reported in previous studies,20,30 25 °C was identified as the
optimum temperature for polyST kinetics over longer incu-
bation periods, whereas reaction velocities were significantly
reduced at 10 °C, and most interestingly at 37 °C. Moreover,
the enzyme also maintained a high initial velocity at 20 °C,
with relatively moderate enzyme activity between 15 °C and
30 °C. The metal ion composition determined in section 3.1.1
was utilised here.
3.1.3 Effect of pH and substrate concentration. The activity
of polyST was examined over a range of pH values (4.90–7.20)
in cacodylate buffer. The optimum pH for a given enzyme reac-
tion can vary with substrate concentration,31 and the buffer
pH has an influence on the KM of substrate,
32 which in turn
can affect the apparent potency (IC50 values) of enzyme inhibi-
tors. With this in mind, we determined the influence of pH on
polyST kinetic parameters, and enzyme reactions were per-
formed at a range of substrate concentrations (10–1000 µM),
and at 50 µM and 150 µM acceptor (DMB-DP3). Initial vel-
ocities were calculated from corresponding enzyme reaction
progress curves (section 2.7), and were plotted against sub-
strate concentration. Data were fit using a non-linear
regression curve, according to the Michaelis–Menten model
(Fig. 4A).
The corresponding kinetic parameters, Vmax, kcat, substrate
(CMP-Sia) KM and catalytic efficiency (kcat/KM) of polyST for
CMP-Sia, measured at both acceptor concentrations, are sum-
marised in Table 1. The results indicate that pH 5.8 was
optimal for catalytic activity, at both low and high concen-
trations of the acceptor. This indicates that the effect of pH on
the catalytic efficiency of polyST is independent of the acceptor
concentration. The catalytic efficiencies, measured at 150 µM
DMB-DP3, were then plotted against pH (Fig. 4B). These
results are consistent with previously reported findings for the
activity of human and chick brain polySTs for NCAM polysialy-
lation with CMP-Sia, albeit in MES buffer and utilising NCAM
as acceptor.23,26,29 It is interesting that the enzyme activity is
apparently optimal in slightly acidic conditions. A potential
explanation for this phenomenon may be due to the pH in the
Golgi apparatus in malignant cells (where this enzyme is
Fig. 3 Effect of temperature on polyST enzyme activity. Data plotted
are mean values ± SD from 3 independent experiments. ***P < 0.0001;
ns = not significant.
Fig. 4 Effect of substrate (CMP-Sia) concentration and pH on enzyme activity. (A) Initial velocities (v0) of enzyme reactions in pH range 4.90–7.20
were plotted as a function of substrate (CMP-Sia) concentration, measured at an acceptor (DMB-DP3) concentration of 150 µM. The plot is a non-
linear regression analysis to the Michaelis–Menten model. Data plotted are mean values ± SD from 3 independent experiments. (B) Effect of pH on
catalytic efficiencies (kcat/KM) at an acceptor concentration of 150 µM. Reactions were carried out at 25 °C, using 20 mM MnCl2.
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usually located) being mildly acidic at pH 5.8–6.2.33,34 The
optimum pH for the assay was thus selected as 5.8.
3.1.4 Effect of enzyme concentration. The effect of polyST
enzyme concentration in the assay was investigated to ensure
steady-state conditions prevailed during the course of the
enzyme reaction, i.e. that a constant (linear) initial velocity was
maintained throughout the reaction course. This requires, gen-
erally, that no more than 15% substrate depletion is observed
at the end-point of an enzyme assay.35 Furthermore, it is also
preferable to keep the enzyme concentration as low as poss-
ible, so as to avoid a high ‘IC50 wall’ for putative tight-binding
inhibitors.36 The optimal enzyme concentration for the assay
was determined by investigating the relationship between
enzyme concentration and reaction velocity at saturated con-
centrations of substrate and acceptor (Fig. 5A), and measuring
the corresponding CMP-Sia conversion (indirectly from
DMB-DP3 to DMB-DP4/DMB-DP5 conversion, as described
above) at a series of enzyme concentrations (Fig. 5B). Assays
were performed under the optimal conditions for ion strength,
temperature and pH described above.
To ensure the final enzyme concentration fell within the
range that provides enzyme reaction linearity, the effect of
enzyme concentration on the reaction velocity was analysed,
and is shown in Fig. 5A. As expected, initial velocity increased
linearly with increased enzyme concentration within the
measured range of 5 to 100 ng µL−1, with saturated concen-
trations of both substrate (500 µM) and acceptor (200 µM).
This indicates that the assay is reliable for quantitative studies
using enzyme concentrations within this range. Next, the
corresponding donor substrate (CMP-Sia) conversion was ana-
lysed at each time point (Fig. 5B). At our routine screening
time point (2 h), substrate conversion was approximately 15%,
when the enzyme concentration was 25 ng µL−1, while the con-
version was lower than 10% when the enzyme concentration
was lower than 15 ng µL−1, in the presence of the saturated
concentrations of CMP-Sia (500 µM) (Fig. 5B). Moreover, the
donor substrate conversion at its original KM (100 µM, pH 6.7)
was also analysed at various enzyme concentrations (Fig. S2†).
Enzyme conversion significantly reduced to approximately 8%
in the presence of 25 ng µL−1 enzyme, and to lower than 3%
when using enzyme concentrations lower than 15 ng µL−1
(Fig. S2†). The low conversion observed at lower enzyme con-
centrations (5–15 ng µL−1) resulted in insufficient fluorescent
signal (from the DMB-DP4 product) for reliable detection. In
contrast, a substrate conversion of higher than 15%/2 h may
not be favourable since the greater substrate depletion will not
provide the ideal steady-state conditions previously
discussed.35,36 With these factors in mind, an enzyme concen-
tration of 25 ng µL−1 (providing a substrate conversion of 8%
at the 2 h screening time point) was thus selected for the opti-
mised assay, with the concentration of CMP-Sia at its KM.
3.1.5 Characteristics of kinetic parameters (KM) for
DMB-DP3. We subsequently measured the kinetic parameters
for the acceptor, DMB-DP3, in the presence of 500 µM
Table 1 Kinetic parameters for the polyST enzyme reaction at 25 °C as a function of pH (utilising initial assay conditions outlined in section 2.3; app
= apparent)
pH
50 µM DMB-DP3 150 µM DMB-DP3
VðappÞmax
(pmol min−1 µg−1)
kcat
(s−1)
KðappÞM
(µM)
kcat/KM
(s−1 M−1)
VðappÞmax
(pmol min−1 µg−1)
kcat
(s−1)
KðappÞM
(µM)
kcat/KM
(s−1 M−1)
5.25 10.41 ± 0.26 7.11 × 10−3 52.39 ± 6.32 135.73 28.82 ± 0.58 0.079 67.32 ± 5.91 1170.31
5.5 9.17 ± 0.19 6.27 × 10−3 34.54 ± 3.39 181.41 27.45 ± 0.84 0.075 39.16 ± 5.71 1916.11
5.8 7.65 ± 0.29 5.23 × 10−3 23.64 ± 5.08 220.95 28.10 ± 0.48 0.077 26.88 ± 2.33 2857.78
6.7 5.57 ± 0.34 3.81 × 10−3 57.29 ± 15.46 66.45 19.20 ± 0.58 0.052 50.34 ± 6.85 1042.50
7.2 3.78 ± 0.36 2.59 × 10−3 92.35 ± 30.16 27.98 15.42 ± 0.42 0.042 86.98 ± 9.33 484.44
Fig. 5 Effect of polyST concentration on reaction initial velocity (A) and conversion of CMP-Sia (B), in the presence of 500 µM CMP-Sia. Data
plotted are mean values ± SD from 3 independent experiments.
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CMP-Sia substrate, to allow sufficient substrate conversion
(Fig. 6). The apparent KM of DMB-DP3 was approximately
230 µM in the optimised assay conditions (pH 5.8), according
to the Michaelis–Menten model. Ideally, keeping the acceptor
at a saturated concentration will favour the screening of com-
pounds that are designed to compete with the substrate (i.e.
CMP-Sia). The DMB-DP3 acceptor concentration had no sig-
nificant effect on the binding affinity of the donor substrate,
however (see section 3.1.3). Given the fluorescent signal for
DMB-DP3 at 100 µM could exceed the linearity range without
further dilution (Fig. S3†), the final concentration of DMB-DP3
was fixed at 50 µM.
3.1.6 Determination of polyST tolerance to DMSO. Limited
aqueous solubility is a common challenge associated with
screening for early hits in inhibitor discovery and DMSO is fre-
quently added to aid solubility and to facilitate preparation of
compound stock solutions. Effects on enzyme kinetics were
evaluated in the assay conditions of MnCl2 (20 mM), at pH 5.8
and 25 °C, over a range of DMSO concentrations (0–5%). The
reaction was initialised by adding substrate (CMP-Sia, 24 µM =
KM). A concentration of DMSO up to 5% did not influence the
enzyme reaction velocity (Fig. 7). A DMSO concentration of 5%
was thus selected (as sufficient to aid compound solubility).
3.2 Assay validation using known polyST inhibitors
In order to test if the assay conditions are suitable for determi-
nation of IC50, mode of inhibition and Ki of potential polyST
inhibitors, we next explored the effect of known compounds
CMP and 5-methyl-CMP (5-Me-CMP).37 CMP and 5-Me-CMP
have both been previously reported as inhibitors of polyST (in
addition to other sialyltransferases).38 Cytidine was also evalu-
ated as a negative control, i.e. a compound known to have no
effect on polyST catalytic activity (structures shown in Fig. 8).
The inhibitory potency of CMP is shown in Fig. 9A. The
inhibitory (IC50) dose–response curves shifting to the right
with increasing concentrations of substrate (CMP-Sia), in the
optimised assay conditions, is consistent with competitive
inhibition. Enzyme kinetic parameters for CMP were thereby
evaluated (Fig. 9B). In the classical Dixon plot (Fig. 9C), lines
intersected in the second quadrant. In the Cornish-Bowden
plot (Fig. S4†), the parallel lines and higher y-intercept ([S]/V0)
values with increased substrate concentration are consistent
with competitive inhibition.39 Taken together, these data
provide further evidence for the competitive mode of inhi-
bition for CMP.
To further evaluate the reliability of the assay in determin-
ing the potency of enzyme inhibitors, the intrinsic potency (Ki)
of CMP was also determined from the Dixon plot, using the
new assay conditions (Fig. 9C and Table 2). Subsequently, the
ratio of the IC50 over the observed Ki was plotted as a function
of the ratio of the substrate over KM. The ratio of IC50/Ki of
CMP increased with increasing substrate concentration
(Fig. 9D), demonstrating that CMP competed with the sub-
strate in the optimised assay conditions. Furthermore, we also
confirmed that CMP does not compete with the acceptor
DMB-DP3 (Fig. S5†).
IC50 is not a direct indicator of enzyme binding affinity,
although the two can be related for competitive inhibitors by
the Cheng–Prusoff equation.40 According to the Cheng–Prusoff
theory for competitive inhibition, the substrate concentration
has distinct effects on the apparent potency (IC50) of inhibitors
of different classes. When the substrate concentration is
lower than its KM, it favours the screening and identification
of competitive inhibitors, and disfavours screening un-
competitive inhibitors, which only bind to substrate-bound
Fig. 7 Effect of DMSO on enzyme reaction velocity.
Fig. 8 Structures of cytidine monophosphate (CMP), 5-methyl-cytidine
monophosphate (5-Me-CMP) and cytidine.
Fig. 6 A Michaelis–Menten plot of polyST initial velocity versus
DMB-DP3 (acceptor) concentration. Data plotted are mean values ± SD
from 3 independent experiments.
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Fig. 9 Assay validation by determining the enzyme inhibitory potency and mode of inhibition of CMP. (A) Concentration-dependent inhibition of
polyST by CMP in the presence of various substrate concentrations; (B) Michaelis–Menten plot of initial velocities for polyST in the presence of
various inhibitor (CMP) concentrations; (C) Dixon plot for the data presented in B, for analysis of intrinsic potency (Ki) of CMP; (D) and (E) changes in
apparent potencies (IC50 values) of CMP as a function of substrate concentration in a semi-log plot (D) and in a linear plot (E); (F) IC50 curves for
CMP and 5-Me-CMP in optimised assay conditions ([S] = KM). Data plotted are mean values ± SD from 3 independent experiments.
Table 2 Summary of measured apparent potencies (IC50) and intrinsic potencies (Ki) for CMP
CMP IC50
(µM)
KM
(CMP-Sia, µM)
Predicted Ki
(µM)
Observed Ki
(µM)
AFE
(Ki)
CMP-Sia (µM) 12 24 48 100
0.5KM KM 2KM 4KM
Optimised assay 33.76 46.16 72.45 112.9 23.64 ± 5.08 22.91 ± 0.521 22.12 ± 0.216 1.043
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enzymes, whereas the substrate concentration has no effect on
changing the apparent potency (IC50) for non-competitive
inhibitors.40–42
The IC50 values of competitive inhibitors are close to their
Ki values when the substrate concentration is significantly
lower than the KM, while the IC50 values of uncompetitive
inhibitors only reflect their Ki values when the substrate con-
centration is significantly higher than the KM. In contrast, the
IC50 values of non-competitive inhibitors are independent
from the concentration of enzyme substrates.40,43 Therefore, in
general, to identify enzyme inhibitors from all modalities, the
most appropriate substrate concentration is at the KM, which
allows for balanced assay conditions, with minimum bias
towards any of these important inhibitor classes.42
To directly determine if the relationship between measured
IC50 and Ki for CMP fits well in the Cheng–Prusoff equation
(IC50/Ki = 1 + [S]/KM), values of (IC50/Ki − 1) were plotted line-
arly against the ratios of [S]/KM, as shown in Fig. 9E. It is clear
that the graph generated from the optimised assay conditions
fits better to the Cheng–Prusoff equation, when the substrate
concentration is five times lower than its KM, than that
obtained from the initial assay conditions (Fig. S6†).
In addition, according to Cheng–Prusoff, the Ki value for a
competitive inhibitor should ideally be 50% of the IC50 value
in a given assay, when the substrate concentration equal to the
KM. Therefore, using IC50/2, the predicted Ki value is reported
alongside the observed Ki for CMP in Table 2. The observed Ki
value correlates well to the predicted value [IC50/2([S] = KM)] in
the optimised assay (average fold error, AFE = 1.043), when
substrate concentrations are in the range of (0.5–4)KM, indicat-
ing feasibility for utilising IC50 values generated within these
substrate concentrations for predicting Ki of CMP.
We next investigated assay sensitivity in terms of being able
to distinguish compounds with potentially similar potencies,
by determining the IC50 value of a CMP analogue (5-Me-CMP),
in comparison to CMP. Cytidine was used as control.
As shown in Fig. 9F, CMP exhibited slightly higher enzy-
matic inhibition than 5-Me-CMP in the optimised assay, and
these results are clearly distinguishable. These relative poten-
cies are in agreement with findings reported for inhibition of
polysialylation of the neural cell adhesion molecule (NCAM)
catalysed by recombinant human polyST enzymes in vitro,
albeit in an assay based on 14C-labelled sialic acid incorpor-
ation into polySia, and subsequent SDS-PAGE of the polymer
produced.37 The negative control, cytidine, had no inhibitory
effects even at 1 mM (as expected).
In summary, these data demonstrate the opportunity to
predict intrinsic potencies (Ki) with confidence from the
corresponding apparent potency values (IC50) at the KM, avoid-
ing the need for extensive kinetic experiments normally
required for such analysis.
3.2.1 Summary of optimised polyST assay conditions.
Recombinant polyST (ST8SiaII) protein (250 ng) and DMB-DP3
(50 µM) were added to an aqueous solution containing MnCl2
(20 mM), and sodium cacodylate (10 mM, pH 5.8, adjusted by
addition of HCl). The reaction was initiated by addition of sub-
strate, CMP-Sia (24 µM), and maintained at 25 °C for 2 h. The
final reaction volume was 10 µl. The enzyme reaction was sub-
sequently quenched by addition of 9 volumes of a stopping
buffer containing Tris-HCl (100 mM, pH 8.0) and EDTA
(20 mM), followed by incubation at 50 °C for 10 min. A 90%
methanol precipitation step was then performed to remove the
recombinant proteins prior to HPLC-fluorescent analysis,
using centrifugation at 14 000 rpm (20 000g).
4. Conclusions
We report a sensitive, accurate, reproducible and robust
enzyme assay for screening novel polyST enzyme inhibitors
that has been optimised through a comprehensive assay devel-
opment process. The optimised assay conditions allow quanti-
tative measurements of polyST activity and compound inhi-
bition, and the usefulness of the assay has been demonstrated
in assessment of full competitive inhibition. These assay con-
ditions additionally provide for the ability to confidently esti-
mate Ki values from IC50 values for enzyme inhibitors. Given
the significant interest in the polyST enzymes as important
anti-metastatic targets in cancer drug discovery, this is a vital
tool to enable identification and quantitative evaluation of
novel polyST inhibitors, and to gain early insight into mode of
inhibition. This work represents an essential step towards ulti-
mately developing a novel clinically-useful therapeutic.
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